Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension

Publisher Website
Google Scholar
Abstract
The influence of angiotensin II AT-1 receptor antagonists on uric acid metabolism, and the potential differences among them with regard to this effect, remains to be precisely established. This study was designed to compare the effects of losartan and eprosartan on uric acid metabolism in patients with mild to moderate essential hypertension. Randomized, double-blind, parallel-group study in hypertensive patients. Outpatient clinic. Following a 2- to 3-week single-blind placebo run-in period, 60 patients with sitting diastolic blood pressure ≥ 95 and ≤ 114 mmHg were randomized. Fifty-eight patients completed the study. Patients were randomized to receive losartan 50 mg or eprosartan 600 mg once daily for 4 weeks. The primary endpoint was the change in the ratio of urinary uric acid/creatinine in the period 0–4 h of a 24 h urine collection after 4 weeks of treatment. Secondary endpoints included 24 h urinary uric acid excretion, as well as serum urate and antihypertensive efficacy. Mean urinary uric acid/creatinine changes from baseline were 0.14 (day 1) and 0.11 (week 4) for losartan and 20.04 for eprosartan (at both day 1 and week 4; P Losartan increased uric acid excretion in hypertensive patients, whilst eprosartan did not. Neither AT-1 receptor antagonist substantially modified serum urate concentrations.